Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models

• Published in: Pulmonary pharmacology & therapeutics 2014-12, Vol.29 (2), p.181-198
• Main Authors: Baker, Katie E, Bonvini, Sara J, Donovan, Chantal, Foong, Rachel E, Han, Bing, Jha, Aruni, Shaifta, Yasin, Smit, Marieke, Johnson, Jill R, Moir, Lyn M
• Format: Article
• Language: English
• Subjects: Animals; Anti-Asthmatic Agents - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Asthma - drug therapy; G-protein coupled receptor; Humans; Inflammation; Kinase; Medical Education; Phosphodiesterase Inhibitors - therapeutic use; Protease Inhibitors - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary/Respiratory; Therapeutic targets; Transient receptor potential channel; Transient Receptor Potential Channels - therapeutic use; Vitamin D; Vitamin D - therapeutic use
• ISSN: 1094-5539; 1522-9629
• DOI: 10.1016/j.pupt.2014.05.008

Abstract Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD.